In 2002 and 2004, preliminary clinical trials of fenofibrate in the treatment of primary biliary cirrhosis were conducted in Japan, and the results suggested that combination therapy with UDCA and fenofibrate was useful in reducing ALP, γ-GT, and IgM levels (19, 20). The gene discussed is CD40LG; the disease is primary biliary cholangitis.